Bladder cancer is the 6th most common type of cancer in the US1
~80,000
~60,000
New cases of bladder cancer in 2020
~80,000
New cases of bladder cancer in 2020
~60,000
The AUA/SUO guideline provides a risk-stratified clinical framework for the management of NMIBC. The rates of recurrence and progression to muscle-invasive bladder cancer (MIBC) are important surrogate endpoints for overall prognosis, as these are major determinants of long-term outcome. Therefore, the ability to predict risk of recurrence and progression and treat the disease appropriately is important.
AUA risk stratification for non-muscle invasive bladder cancer
LOW-RISK
LGa solitary Ta ≤ 3cm
PUNLMPb
INTERMEDIATE-RISK
Solitary LG Ta > 3cm
HGc Ta, ≤ 3cm
HIGH-RISK
aLG = low grade; bPUNLMP = papillary urothelial neoplasm of low malignant potential; cHG = high grade; dCIS = carcinoma in situ; eLVI = lymphovascular invasion
UP TO 43%
A large proportion of high-risk patients will experience recurrence following intravesical therapy6
Up to
Up to
IT’S TIME FOR MORE OPTIONS
IN HIGH-RISK NMIBC >
IT’S TIME FOR MORE OPTIONS
IN HIGH-RISK NMIBC >
References: 1. SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 7, 2021. 2. American Urological Association. (2020). Diagnosis and Treatment of Non Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020). https://www.auanet.org//guidelines/bladder-cancer-non-muscle-invasive-guideline. 3. Anastasiadis A, De Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4(1):13-32. 4. Danforth KN, Sidell MA, Luong TQ, et al.Care quality and variability in the use of intravesical therapy for initial treatment of non-muscle invasive bladder cancer within a large, diverse integrated delivery system. Urology. 2019. https://doi.org/10.1016/j.urology.2019.03.035. [Epub ahead of print.] 5. Williams S, Luong T, Yi D, et al. Initial treatment of non-muscle invasive bladder cancer (NMIBC) in a large integrated delivery system. J Urol. 2018;199(4s):e948. 6. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27(34): 5680-5684.
Copyright FerGene, Inc. 2020/11 US-URONC-2000010